Reversal of HER2 Negativity: An Unexpected Role for Lovastatin in Triple-Negative Breast Cancer Stem Cells.
HER2
cancer stem cell
cancer therapy
lovastatin
reversal
triple-negative breast cancer
Journal
Journal of Cancer
ISSN: 1837-9664
Titre abrégé: J Cancer
Pays: Australia
ID NLM: 101535920
Informations de publication
Date de publication:
2020
2020
Historique:
received:
12
08
2019
accepted:
14
11
2019
entrez:
25
4
2020
pubmed:
25
4
2020
medline:
25
4
2020
Statut:
epublish
Résumé
Effective treatment modality for triple-negative breast cancer (TNBC) is currently lacking due to the absence of defined receptor targets. Recently, we have demonstrated that lovastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor and a lipid-lowering drug, can selectively inhibit TNBC by targeting cancer stem cells
Identifiants
pubmed: 32328175
doi: 10.7150/jca.39265
pii: jcav11p3713
pmc: PMC7171481
doi:
Types de publication
Journal Article
Langues
eng
Pagination
3713-3716Informations de copyright
© The author(s).
Déclaration de conflit d'intérêts
Competing Interests: The authors have declared that no competing interest exists.
Références
Nat Rev Clin Oncol. 2010 Dec;7(12):683-92
pubmed: 20877296
ACS Appl Mater Interfaces. 2018 Feb 28;10(8):7022-7030
pubmed: 29405062
Anticancer Drugs. 2014 Aug;25(7):735-44
pubmed: 24637578
J Cancer. 2018 Sep 8;9(20):3723-3727
pubmed: 30405843
J Cancer. 2016 Jan 01;7(2):192-9
pubmed: 26819643
CA Cancer J Clin. 2014 Jul-Aug;64(4):252-71
pubmed: 24890451
Lancet Oncol. 2007 Mar;8(3):235-44
pubmed: 17329194
Lancet. 1989 Jan 28;1(8631):182-5
pubmed: 2463445
Lancet. 1985 Feb 16;1(8425):364-6
pubmed: 2857419
N Engl J Med. 2010 Nov 11;363(20):1938-48
pubmed: 21067385
Breast Cancer Res Treat. 2014 Apr;144(2):405-16
pubmed: 24557337
Cancer Treat Rev. 2010 May;36(3):206-15
pubmed: 20060649